Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicenter Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian Federation (ROMERUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03549143
Recruitment Status : Completed
First Posted : June 7, 2018
Last Update Posted : April 25, 2019
Sponsor:
Information provided by (Responsible Party):
Abbott

Brief Summary:
Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian Federation

Condition or disease Intervention/treatment
Irritable Bowel Syndrome Other: IBS

Detailed Description:
Awareness about the disease in Russia is extremely low both among doctors and especially among patients. To date there are no data on the prevalence of the disease in Russia. This is the first study to show patient profile, main trigger factors and concomitant diseases among patients with Irritable Bowel Syndrome (IBS) in Russia. Also treatment characteristics for these patients in Russia will be measured. This study fills a lack of scientific data about prevalence of IBS and additional information.

Layout table for study information
Study Type : Observational
Actual Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Multicenter Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian Federation
Actual Study Start Date : December 25, 2017
Actual Primary Completion Date : April 19, 2019
Actual Study Completion Date : April 19, 2019

Intervention Details:
  • Other: IBS
    No intervention, description of routine practice only


Primary Outcome Measures :
  1. Proportion of patients with IBS according to Rome IV Diagnostic Criteria by sex [ Time Frame: Baseline ]
  2. Proportion of patients with IBS according to Rome IV Diagnostic Criteria by education [ Time Frame: Baseline ]
  3. Proportion of patients with IBS according to Rome IV Diagnostic Criteria by region of living [ Time Frame: Baseline ]
  4. Proportion of patients with IBS according to Rome IV Diagnostic Criteria by marriage status [ Time Frame: Baseline ]
  5. Proportion of patients with IBS according to Rome IV Diagnostic Criteria by type of IBS [ Time Frame: Baseline ]

Secondary Outcome Measures :
  1. Findings of routine examination [ Time Frame: 6 months ]
    proportion of patients with confirmed IBS by routine examination among all patients met Rome IV criteria

  2. Comorbidity [ Time Frame: Baseline ]
    Proportion of patients with different diagnosis registered at baseline

  3. Routine treatment regimens [ Time Frame: Baseline, 6 months ]
    Proportion of patients received each treatment

  4. Absolute score of the IBS symptoms measured by IBS-QoL scale [ Time Frame: Baseline, 1, 2, 4, and 6 months ]
    Irritable Bowel Syndrome - Quality Of Life (IBS-QOL) questionnaire contains 34 questions assessed from 1 point = "not at all" till 5 point = "a great deal". The sum of all items is used to calculate the total score. All items are negative framed with the greatest response scale equaling the worst QoL. Scores for all items are transformed to a 0 to 100 scale, ranging from 0 (worst QoL) to 100 (best QoL).

  5. Changes from baseline of the IBS symptoms measured by IBS-QoL scale [ Time Frame: Baseline, 1, 2, 4, and 6 months ]
    Irritable Bowel Syndrome - Quality Of Life (IBS-QOL) questionnaire contains 34 questions assessed from 1 point = "not at all" till 5 point = "a great deal". The sum of all items is used to calculate the total score. All items are negative framed with the greatest response scale equaling the worst QoL. Scores for all items are transformed to a 0 to 100 scale, ranging from 0 (worst QoL) to 100 (best QoL). Positive change corresponds to better outcome.

  6. Assesment by Global Patient Assessment scale [ Time Frame: 1, 2, 4, and 6 months ]
    Global Patient Assessment contains one question to rate up patient's general complaints of GI-discomfort. A 5-point Likert scale is used as follow: `symptom-free, markedly improved, slightly improved, unchanged, worse`.

  7. Assesment by Physician Global Assessment scale [ Time Frame: 1 and 6 months ]
    Physician Global Assessment contains one question to rate up patient's general complaints of GI-discomfort. A 5-point Likert scale is used as follow: `symptom-free, markedly improved, slightly improved, unchanged, worse`.

  8. Adherence to treatment [ Time Frame: up to 6 months ]
    The national questionnaire of treatment compliance contains 5 questions with 4 answers each. The sum of all items is used to calculate the total score. The total score has the range from 0 (worst compliance) to 15 (best compliance).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
adult subjects, male and female, aged from 18 up to 50 years with symptoms potentially indicative of IBS according to ROME IV criteria
Criteria

Inclusion Criteria:

  • Male or female 18-50 y.o
  • Patients suffering from Irritable bowel syndrome (abdominal pain and changes in bowel habit) as defined by Rome IV criteria and the absence of any relevant structural disease
  • Patient's written authorization to provide data for the program
  • Patients who are able to input him/herself data into patients' part of Electronic Data Capture (EDC)

Exclusion Criteria:

Presence of alarm features:

  • positive family history of colorectal cancer, inflammatory bowel disease, celiac disease
  • rectal bleeding in the absence of documented bleeding hemorrhoids or anal fissures
  • unintentional weight loss
  • severe anemia (according to local laboratory reference values)
  • Fever (> 37,5 degree Celsius)
  • Night symptoms appearance

Other:

  • Significant and progressive change in: enlargement of the liver, spleen, lymph nodes; ascites; palpable mass in the abdomen / pelvic
  • Pregnancy or lactation or the inability to use adequate contraception during the study;
  • Other conditions that made the patients participation impossible (by investigator judgment)
  • Previous enrollment in any other clinical study during the course of this study, including participation in a study within 30 days prior to informed consent.
  • Prescribed by Health Care Professional(s) (HCP) and being currently treated or having been treated with spasmolytics within the 3 months prior to entering the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03549143


Locations
Layout table for location information
Russian Federation
City Clinical Hospital #8
Chelyabinsk, Russian Federation, 454007
Railway Clinical Hospital
Irkutsk, Russian Federation, 664005
City Clinical Hospital #4
Ivanovo, Russian Federation, 153005
The First Republican Clinical Hospital of MoH UR
Izhevsk, Russian Federation, 426039
Interregional Clinical Diagnostic Center
Kazan, Russian Federation, 420101
Medical Center "Dobryj Doctor"
Kemerovo, Russian Federation, 650000
Branch Hospital AT ST. Krasnodar JSC "RZD"
Krasnodar, Russian Federation, 350072
The Medical ON Group Lyubertsy
Lyubertsy, Russian Federation, 140002
Institute of Health
Lyubertsy, Russian Federation, 140013
SM-Clinic
Lyubertsy, Russian Federation, 140013
Multidisciplinary Medical Clinic
Moscow, Russian Federation, 111123
Research Institute of gastroenterology
Moscow, Russian Federation, 111123
Medical Center 'Golden Orchid'
Moscow, Russian Federation, 111675
Outpatient Dpt of City Clinical Hospital #85
Moscow, Russian Federation, 115409
Blokhin Oncology Center
Moscow, Russian Federation, 115522
9 MDC Ministry of Defense
Moscow, Russian Federation, 119021
Medical Center on Timur Frunze Street
Moscow, Russian Federation, 119021
MEDSI Clinic
Moscow, Russian Federation, 123056
CP Litfonda
Moscow, Russian Federation, 125319
Diamed Clinic
Moscow, Russian Federation, 125368
MC Larmed
Moscow, Russian Federation, 125475
Clinic 'Medic City'
Moscow, Russian Federation, 127220
MSMSU them. A. I. Evdokimov
Moscow, Russian Federation, 127473
CPM LLC
Novosibirsk, Russian Federation, 630090
LLC Multidisciplinary Medical Center ALTAME+
Odintsovo, Russian Federation, 143006
LLC Industrial Medicine Clinic, polyclinic No1
Orenburg, Russian Federation, 46000
Treatment and Rehabilitation Center No1
Rostov-on-Don, Russian Federation, 344011
Medi Com LLC (SM-clinic)
Saint Petersburg, Russian Federation, 195279
LLC 'Avesta MDC-M'
Saratov, Russian Federation, 410028
Stavropol Regional Clinical Diagnostic Center
Stavropol, Russian Federation, 355017
OKD Diagnostic Center
Surgut, Russian Federation, 628415
Consulvative and Diagnostic Center Endos
Tyumen, Russian Federation, 625026
Kuvatov RCH
Ufa, Russian Federation, 450005
Diamed Llc
Vladivostok, Russian Federation, 690087
MC Medic LLC
Yekaterinburg, Russian Federation, 620014
MC Chance LLC
Yekaterinburg, Russian Federation, 620143
LLC "Medical Center" Doctor Plus
Yekaterinburg, Russian Federation, 6220018
Sponsors and Collaborators
Abbott

Layout table for additonal information
Responsible Party: Abbott
ClinicalTrials.gov Identifier: NCT03549143     History of Changes
Other Study ID Numbers: EPIDI060
First Posted: June 7, 2018    Key Record Dates
Last Update Posted: April 25, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Abbott:
IBS; Irritable Bowel Syndrome; spasmolytics; mebeverine; Duspatalin

Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Irritable Bowel Syndrome
Disease
Pathologic Processes
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases